Our diagnostics platform centers on the long isoform of QSOX1 (QSOX1-L). We are developing rapid diagnostic tests that detect QSOX1-L using proprietary antibodies. These tests will allow us to correlate levels of QSOX1-L with stage of cancer, recurrence or response to therapy. Early data suggest that levels of QSOX1-L are elevated in individuals with cancer compared to healthy individuals.
For the table below, everything is in pre-clinical development.
COMPANION DIAGNOSTIC TEST
Axim is developing a companion diagnostic test to monitor QSOX1-L in the blood of patients receiving any anti-cancer treatment whose tumors over-express QSOX1. Pre-clinical testing is ongoing in human triple-negative breast cancer xenograft models.
If QSOX1-L levels increase during treatment it suggests that treatment is ineffective so the patient would switch to another treatment.
IMMUNOHISTOCHEMISTRY (IHC) DIAGNOSTIC TEST
AXIM has licensed anti-QSOX1 monoclonal antibodies from Skysong Innovations and has developed polyclonal antibodies in-house. These antibodies will be tested in IHC for staging different tumor types.
AXIM continues research and development relating to QSOX1-L with the objective of studying QSOX1 levels in blood at various stages of cancer. The Company has already tested over 200 bladder cancer samples seeking to establish a correlation of QSOX1-L levels with tumor progression. In addition, the Company’s test is currently the subject of an ongoing Clinical Trials relating to pancreatic cancer samples. The ultimate goal is to validate QSOX1-L as a blood biomarker for cancer.